PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Bevacizumab gamma - Wet age-related macular degeneration

PAD Profile : Bevacizumab gamma - Wet age-related macular degeneration

Keywords :
wet AMD, Ophthalmology, blindness, eyes, retinal, retina, NICE
Brand Names Include :
Lytenava

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravitreal injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
ICB
NICE
Comments :
No comments returned.

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
01 January 2025
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves bevacizumab gamma as a treatment option for the treatment of wet age-related macular degeneration as recommended by NICE TA1022

Bevacizumab gamma for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More